Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.51 |
| ▸ | CYP2A6 | P11509 | 5/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | METAP2 | P50579 | 1/20 | 0.47 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.47 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11598851 | 0.80 | SMN1; SMN2 (0.87) | SMN1; SMN2ALDH1A1TP53KDM4ELMNA | |
| SCHEMBL1436121 | 0.79 | NR1H2 (0.61) | SMN1; SMN2TP53LMNAHPGDCYP1A2 | |
| SCHEMBL831106 | 0.79 | SMN1; SMN2 (0.63) | SMN1; SMN2ALDH1A1TP53KDM4ELMNA | |
| SCHEMBL4873033 | 0.79 | SMN1; SMN2 (0.63) | SMN1; SMN2ALDH1A1TP53KDM4ELMNA | |
| SCHEMBL6263112 | 0.78 | SMN1; SMN2 (0.58) | SMN1; SMN2ALDH1A1TP53KDM4ELMNA | |
| SCHEMBL12282613 | 0.78 | SMN1; SMN2 (0.58) | SMN1; SMN2ALDH1A1TP53KDM4ELMNA | |
| SCHEMBL16071467 | 0.78 | SMN1; SMN2 (0.58) | SMN1; SMN2ALDH1A1TP53KDM4ELMNA | |
| SCHEMBL17279680 | 0.77 | SMN1; SMN2 (1.00) | SMN1; SMN2ALDH1A1TP53KDM4ELMNA | |
| SCHEMBL29330535 | 0.77 | HDAC3 (0.53) | KDM4EJAK2MAPK8MAPK9 | |
| SCHEMBL26107873 | 0.76 | HDAC3 (0.65) | LMNAGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3519403-B1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | MIRONID LTD (GB) | 2021-09-08 | — | — | EP | disclosed |
| US-11046660-B2 | Compounds and their use as PDE4 activators | MIRONID LIMITED (GB) | 2021-06-29 | — | — | US | disclosed |
| EP-3725785-A1 | GLUTARIMIDE DERIVATIVES, USE THEREOF, PHARMACEUTICAL COMPOSITION BASED THEREON AND METHODS FOR PRODUCING GLUTARIMIDE DERIVATIVES | Obschestvo S Ogranichennoi Otvetstennostiyu "Pharmenterprises" (RU) | 2020-10-21 | — | — | EP | disclosed |
| EP-3722290-A1 | GLUTARIMIDE DERIVATIVES, USE THEREOF, PHARMACEUTICAL COMPOSITION BASED THEREON AND METHODS FOR PRODUCING GLUTARIMIDE DERIVATIVES | Obschestvo S Ogranichennoi Otvetstennostiyu "Pharmenterprises" (RU) | 2020-10-14 | — | — | EP | disclosed |
| US-20200031781-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | MIRONID LIMITED (GB) | 2020-01-30 | — | — | US | disclosed |
| US-10377739-B2 | Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives | Obschestvo S Ogranichennoi Otvetstvennostiyu “Pharmenterprises” (RU) | 2019-08-13 | — | — | US | disclosed |
| US-20190084961-A1 | Glutarimide Derivatives, Use Thereof, Pharmaceutical Composition Based Thereon and Methods for Producing Glutarimide Derivatives | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU "PHARMENTERPRISES" (RU) | 2019-03-21 | — | — | US | disclosed |
| US-10196377-B2 | Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives | Obschestvo S Ogranichennoi Otvetstvennostiyu “Pharmenterprises” (RU) | 2019-02-05 | — | — | US | disclosed |
| US-20180022728-A1 | Glutarimide Derivatives, Use Thereof, Pharmaceutical Composition Based Thereon and Methods for Producing Glutarimide Derivatives | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU "PHARMENTERPRISES" (RU) | 2018-01-25 | — | — | US | disclosed |
| US-20180022728-A1 | Glutarimide Derivatives, Use Thereof, Pharmaceutical Composition Based Thereon and Methods for Producing Glutarimide Derivatives | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU "PHARMENTERPRISES" (RU) | 2018-01-25 | — | — | US | disclosed |
| WO-2013120980-A1 | TRICYCLIC COMPOUNDS AND METHODS OF USE THEREFOR | F. HOFFMANN-LA ROCHE AG (CH) | 2013-08-22 | — | — | WO | disclosed |
| EP-1441719-B1 | N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-03-30 | — | — | EP | disclosed |
| US-7803819-B2 | DPP IV inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2010-09-28 | — | — | US | disclosed |
| US-7314884-B2 | non-insulin dependent diabetes mellitus, and impaired glucose tolerance; dipeptidyl peptidase IV (DPP-IV) inhibitors eg (2S)-1-{[(1S)-2-(5-cyano-2-methyl-indol-1-yl)-1-methyl-ethylamino]-acetyl}-pyrrolidine-2-carbonitrile | HOFFMANN-LA ROCHE INC. (US) | 2008-01-01 | — | — | US | disclosed |
| US-20070259925-A1 | DPP IV INHIBITORS | BOEHRINGER MARKUS | 2007-11-08 | — | — | US | disclosed |
| US-20050096348-A1 | DPP IV inhibitors | BOEHRINGER MARKUS (CH) | 2005-05-05 | — | — | US | disclosed |
| US-6861440-B2 | DPP IV inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2005-03-01 | — | — | US | disclosed |
| EP-1441719-A1 | N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-04 | — | — | EP | disclosed |
| US-20030130281-A1 | DPP IV inhibitors | HOFFMAN-LA ROCHE INC. | 2003-07-10 | — | — | US | disclosed |
| WO-2003037327-A1 | N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | F. HOFFMANN-LA-ROCHE AG (CH) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10377739-B2 | Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives | GCDH, GLS, HADH | SMN1; SMN2 1508/4885ALDH1A1 799/4885TP53 4744/4885 |
| US-20180022728-A1 | Glutarimide Derivatives, Use Thereof, Pharmaceutical Composition Based Thereon and Methods for Producing Glutarimide Derivatives | GCDH, GLS, HADH | SMN1; SMN2 1377/4885ALDH1A1 800/4885TP53 4730/4885 |
| US-11046660-B2 | Compounds and their use as PDE4 activators | PDE4A, PDE4B, PDE7A | SMN1; SMN2 1128/4885ALDH1A1 611/4885TP53 4813/4885 |
| US-10196377-B2 | Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives | GCDH, GLS, HADH | SMN1; SMN2 1508/4885ALDH1A1 799/4885TP53 4744/4885 |
| US-20190084961-A1 | Glutarimide Derivatives, Use Thereof, Pharmaceutical Composition Based Thereon and Methods for Producing Glutarimide Derivatives | GCDH, GLS, HADH | SMN1; SMN2 1508/4885ALDH1A1 799/4885TP53 4744/4885 |
| US-20200031781-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | PDE4A, PDE4B, PDE7A | SMN1; SMN2 1128/4885ALDH1A1 611/4885TP53 4813/4885 |
| US-20070259925-A1 | DPP IV INHIBITORS | DPP4, DPP3, DPP7 | SMN1; SMN2 2529/4885ALDH1A1 233/4885TP53 4661/4885 |
| US-20030130281-A1 | DPP IV inhibitors | DPP4, DPP3, DPP7 | SMN1; SMN2 1935/4885ALDH1A1 133/4885TP53 4814/4885 |
| US-20050096348-A1 | DPP IV inhibitors | DPP4, DPP3, DPP7 | SMN1; SMN2 2529/4885ALDH1A1 233/4885TP53 4661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.